Drug Information

Drug General Information
Drug ID
D07GQP
Former ID
DNC004689
Drug Name
PG-01037
Drug Type
Small molecular drug
Indication Discovery agent Investigative [541780]
Structure
Download
2D MOL

3D MOL
Formula
C26H26Cl2N4O
InChI
InChI=1S/C26H26Cl2N4O/c27-22-6-5-8-24(25(22)28)32-18-16-31(17-19-32)15-4-3-14-30-26(33)21-11-9-20(10-12-21)23-7-1-2-13-29-23/h1-13H,14-19H2,(H,30,33)/b4-3+
InChIKey
ZMYOIZHRXABMFZ-ONEGZZNKSA-N
PubChem Compound ID
11477180
PubChem Substance ID
16577963, 23613195, 42556096, 77392925, 85229532, 103440257, 104047571, 134224273, 134341894, 178103287
Target and Pathway
Target(s) 5-hydroxytryptamine 2C receptor Target Info Inhibitor [528974]
D(2) dopamine receptor Target Info Inhibitor [528974]
D(4) dopamine receptor Target Info Inhibitor [528974]
5-hydroxytryptamine 1A receptor Target Info Inhibitor [528974]
5-hydroxytryptamine 2A receptor Target Info Inhibitor [528974]
D(3) dopamine receptor Target Info Inhibitor [528974]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channelshsa04015:Rap1 signaling pathway
cAMP signaling pathway
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
Dopaminergic synapsehsa04024:cAMP signaling pathway
Serotonergic synapsehsa04020:Calcium signaling pathway
Inflammatory mediator regulation of TRP channelshsa04080:Neuroactive ligand-receptor interaction
PANTHER Pathway 5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
Genes and (Common) Pathways Underlying Drug Addiction
GPCR downstream signaling
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
Nicotine Activity on Dopaminergic Neurons
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
GPCRs, OtherWP58:Monoamine GPCRs
GPCRs, Other
References
Ref 541780(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6675).
Ref 528974J Med Chem. 2007 Aug 23;50(17):4135-46. Epub 2007 Aug 2.Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.